Neurological symptoms observed after IVM or MOX administration in Mdr1ab(−/−) mice.

The Mdr1ab(−/−) mice (3 per dose rate) injected subcutaneously at dose rates of 0.11, 0.40 and 0.69 µmol/kg bw for IVM and 1.27, 1.64 and 2.56 µmol/kg bw for MOX were observed and the development of symptoms evoking neurologic signs (rapid breathing, balance problems, tremor, ataxia, sleepiness, lethargy) was recorded over a period of 2 weeks; every 60 min for the first 12 hours and thence minimally twice per day. Mice were euthanized when severe tremors or ataxia or profound lethargy was noted.†Mice were euthanized when severe tremor or ataxia was noted.aDose rate averaging the LD50 for IVM.bDose rate averaging the LD50 for MOX.cAtaxia: lack of voluntary coordination of muscle movements, as in walking.dTremor: rhythmic, muscle contraction and relaxation involving oscillations or twitching.